Cargando…
A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib
Triple negative breast cancers (TNBC) have poor prognosis compared to other breast cancer subtypes and represent 15-20% of breast cancers diagnosed. Unique targets and new molecularly-targeted therapies are urgently needed for this subtype. Despite high expression of Epidermal Growth Factor Receptor...
Autores principales: | Ebelt, Nancy D., Kaoud, Tamer S., Edupuganti, Ramakrishna, Van Ravenstein, Sabrina, Dalby, Kevin N., Van Den Berg, Carla L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739608/ https://www.ncbi.nlm.nih.gov/pubmed/29285221 http://dx.doi.org/10.18632/oncotarget.20581 |
Ejemplares similares
-
c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression
por: Cantrell, Michael A., et al.
Publicado: (2015) -
Alarmins and c-Jun N-Terminal Kinase (JNK) Signaling in Neuroinflammation
por: Anfinogenova, Nina D., et al.
Publicado: (2020) -
The Roles of c-Jun N-Terminal Kinase (JNK) in Infectious Diseases
por: Chen, Jing, et al.
Publicado: (2021) -
Stressor-Like Effects of c-Jun N-Terminal Kinase (JNK) Inhibition
por: Clarke, Melanie, et al.
Publicado: (2012) -
Molecular docking of C-Jun-N-Terminal Kinase (Jnk) with amino-pyrimidine derivatives
por: Meenakumari, Krishnamoorthy, et al.
Publicado: (2020)